Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY044
MIFTS: 54

Larynx Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Larynx Cancer

About this section

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer 12 15
Laryngeal Carcinoma 12 74 52 54 15
Laryngeal Cancer 52 36 54
Malignant Neoplasm of Larynx 71 32
Carcinoma of Larynx 12 71
Laryngeal Neoplasm 17 71
Laryngeal Neoplasms 43
Cancer, Laryngeal 39
Cancer of Larynx 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Skin diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2596 DOID:2600
KEGG 36 H00055
ICD9CM 34 161 161.9
MeSH 43 D007822
NCIt 49 C4855 C7484
SNOMED-CT 67 93859007
ICD10 32 C32 C32.9
UMLS 71 C0007107 C0023055 C0595989
Sources

Summaries for Larynx Cancer

About this section
KEGG : 36 Laryngeal cancer is one of the most common malignancies in Europe, with about 52,000 new cases per year, 90% of them occurring in men. Smoke and alcohol represent the major behavioral risk factors. Of all laryngeal cancers, some 95% are squamous cell carcinomas. Some molecular events have been described in laryngeal squamous cell carcinoma (LSCC). Although tumor suppressor inactivation of p53 and p16 is common in these tumors (about 50% each), oncogenic activation is less well characterized. Cyclin D1 and epidermal growth factor receptor amplification have been reported in one-third and one-quarter of LSCCs, respectively, both related to advanced stages, whereas c-myc could be amplified in 13% of cases although without associated overexpression.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to suppressor of tumorigenicity 3 and hypopharynx cancer. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and thyroid.

Disease Ontology : 12 A larynx cancer that has material basis in epithelial cells.

Wikipedia : 74 Laryngeal cancer are mostly squamous cell carcinomas, reflecting their origin from the skin of the... more...

Sources

Related Diseases for Larynx Cancer

About this section

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.8 TP53 CDKN2A
2 hypopharynx cancer 30.8 TP53 NME1 EGFR CDKN2A
3 squamous cell carcinoma 30.7 TP53 NME1 GSTP1 EGFR CDKN2A CCND1
4 small cell carcinoma 30.7 TP53 EGFR CDKN2A
5 basaloid squamous cell carcinoma 30.6 TP53 EGFR CDKN2A
6 malignant peritoneal mesothelioma 30.5 EGFR CDKN2A
7 cervical intraepithelial neoplasia 30.5 TERT NME1 CDKN2A
8 dermatomyositis 30.5 MIR34A MIR21 MIR148A
9 keratinizing squamous cell carcinoma 30.5 TP53 EGFR CDKN2A
10 verrucous carcinoma 30.4 TP53 EGFR CDKN2A CCND1
11 papilloma 30.4 TP53 EGFR CDKN2A CCND1
12 oropharynx cancer 30.4 TP53 EGFR CDKN2A CCND1
13 mutagen sensitivity 30.4 TP53 NAT2 GSTM1 CCND1
14 mucoepidermoid carcinoma 30.4 TP53 EGFR CDKN2A CCND1
15 esophagitis 30.3 TP53 EGFR CDKN2A
16 keratosis 30.3 TP53 EGFR CDKN2A
17 papillary squamous carcinoma 30.3 EGFR CDKN2A
18 inverted papilloma 30.3 TP53 EGFR CDKN2A CCND1
19 leiomyosarcoma 30.3 TP53 CDKN2A CCND1
20 cervical adenocarcinoma 30.3 TP53 EGFR CDKN2A
21 colon adenocarcinoma 30.3 TP53 MIR21 EGFR CCND1
22 breast adenocarcinoma 30.2 TP53 HSPB1 GSTP1 EGFR CTSD
23 thymoma 30.2 TP53 EGFR CDKN2A CCND1
24 laryngeal squamous cell carcinoma 30.2 TP53 TERT NME1 MIR34A MIR21 MIR148A
25 supraglottis cancer 30.2 EGFR CDKN2A
26 tongue cancer 30.2 TP53 TERT MIR21 FAM3D-AS1 EGFR CDKN2A
27 glioma susceptibility 1 30.1 TP53 MIR34A MIR21 EGFR CDKN2A
28 transitional cell carcinoma 30.1 TP53 NME1 GSTP1 GSTM1 EGFR CDKN2A
29 oral cancer 30.1 TP53 MIR21 GSTM3 GSTM1 EGFR CDKN2A
30 in situ carcinoma 30.1 TP53 MIR423 MIR106B EGFR CDKN2A CCND1
31 kidney cancer 30.0 TP53 MIR21 MIR106B GSTP1 EGFR CDKN2A
32 lynch syndrome 30.0 TP53 TERT GSTP1 GSTM1 EGFR CDKN2A
33 oral cavity cancer 30.0 TP53 MIR423 MIR21 GSTM1 EGFR CDKN2A
34 myeloma, multiple 30.0 TP53 MIR21 MIR106B EGFR CDKN2A CCND1
35 basal cell carcinoma 29.9 TP53 TERT HSPB1 GSTM3 GSTM1 EGFR
36 glioblastoma multiforme 29.8 TP53 TERT MIR34A MIR21 EGFR CDKN2A
37 melanoma 29.8 TP53 TERT MIR34C MIR34A EGFR CDKN2A
38 laryngeal disease 29.7 TP53 MIR423 MIR34C MIR34A MIR21 MIR148A
39 pharynx cancer 29.7 TP53 MIR423 MIR34C MIR21 GSTM3 GSTM1
40 squamous cell carcinoma, head and neck 29.6 CCND1 TP53 NME1 MIR423 MIR21 MIR148A
41 renal cell carcinoma, nonpapillary 29.5 TP53 NME1 MIR423 MIR34A MIR21 MIR106B
42 lung cancer susceptibility 3 29.5 TP53 TERT MIR423 MIR21 MIR148A GSTP1
43 nasopharyngeal carcinoma 29.4 TP53 TERT NME1 MIR423 MIR34C MIR21
44 bladder cancer 29.3 TP53 TERT NAT2 MIR34A MIR21 MIR106B
45 leukemia, acute myeloid 29.3 TP53 TERT MIR423 MIR34C MIR34A MIR21
46 pancreatic cancer 29.2 TP53 TERT MIR34C MIR34A MIR21 MIR148A
47 cervical cancer 29.2 TP53 TERT NME1 MIR34C MIR34A MIR21
48 gastric cancer 29.2 TP53 TERT NME1 MIR423 MIR34A MIR21
49 esophageal cancer 29.2 TP53 TERT MIR423 MIR34A MIR21 MIR148A
50 breast cancer 29.1 TP53 TERT NME1 NAT2 MIR34A MIR21

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):


Bronchitis Deficiency Anemia
Pharynx Cancer Protein-Energy Malnutrition
Respiratory Failure Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:



Diseases related to Larynx Cancer
Sources

Symptoms & Phenotypes for Larynx Cancer

About this section
Sources

Drugs & Therapeutics for Larynx Cancer

About this section

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4 Liver Extracts Phase 4
5 Central Nervous System Stimulants Phase 4
6 Nicotinic Agonists Phase 4
7 Cholinergic Agents Phase 4
8 Dopamine Uptake Inhibitors Phase 4
9 Cytochrome P-450 Enzyme Inhibitors Phase 4
10 Dopamine Agents Phase 4
11 Psychotropic Drugs Phase 4
12 Antidepressive Agents Phase 4
13 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
14
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
15
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
16
Cefazolin Approved Phase 3 25953-19-9 656510 33255
17
Ethanol Approved Phase 3 64-17-5 702
18
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
19
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
20
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
21
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
22
Pembrolizumab Approved Phase 2, Phase 3 1374853-91-4
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
24
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
25
Mitoguazone Investigational Phase 2, Phase 3 459-86-9
26 Vitamins Phase 3
27 Hypolipidemic Agents Phase 3
28 Vitamin B Complex Phase 3
29 Vitamin B3 Phase 3
30 Folate Phase 3
31 Vitamin B9 Phase 3
32 Lipid Regulating Agents Phase 3
33 Nicotinic Acids Phase 3
34 Vasodilator Agents Phase 3
35 Muscarinic Agonists Phase 2, Phase 3
36 Immunoglobulin G Phase 2, Phase 3
37 Antimitotic Agents Phase 2, Phase 3
38 Antibodies, Monoclonal Phase 2, Phase 3
39
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
40
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
41
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
42
Indinavir Approved Phase 2 150378-17-9 5362440
43
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
44
Zinc Approved, Investigational Phase 2 7440-66-6 32051
45
Zinc oxide Approved Phase 2 1314-13-2
46
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
47
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 234)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
4 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
5 Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery Completed NCT00467948 Phase 3 cefazolin
6 A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma. Completed NCT00147732 Phase 3
7 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
8 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
9 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
10 DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality. Completed NCT00359645 Phase 3
11 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
12 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
13 PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS Completed NCT00002839 Phase 3 cisplatin;fluorouracil
14 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
15 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
16 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
17 A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012, With and Without Chemotherapy, in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Not yet recruiting NCT04129320 Phase 2, Phase 3 Chemotherapeutic Combinations
18 Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers Terminated NCT00128817 Phase 3
19 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
20 Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF) Unknown status NCT01073683 Phase 2 Taxotere (Docetaxel), Cisplatin, 5FU
21 A Phase II Study of Induction Chemotherapy Followed by Concomitant Paclitaxel (1 Hour Infusion), Fluorouracil, Hydroxyurea and Hyperfractionated Radiotherapy for Advanced Oral, Pharynx and Larynx Cancer Unknown status NCT00004094 Phase 2 carboplatin;fluorouracil;hydroxyurea;paclitaxel
22 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
23 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
24 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
25 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
26 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
27 Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer Unknown status NCT02262221 Phase 2
28 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
29 Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer Completed NCT00004256 Phase 2
30 Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer Completed NCT02849314 Phase 1, Phase 2
31 A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Completed NCT00765011 Phase 2 TPF, radiotherapy and cetuximab
32 Clinical Feasibility of a New Surgical Tool for Primary or Secondary Tracheoesophageal Puncture and Voice Prosthesis Insertion for Prosthetic Voice Rehabilitation After Total Laryngectomy Completed NCT01045057 Phase 1, Phase 2
33 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
34 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
35 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
36 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
37 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
38 Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy Completed NCT00026975 Phase 2
39 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
40 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
41 Early Stage Glottic Cancer: Endoscopic Excision or Radiotherapy [EaStER] Completed NCT00334997 Phase 2
42 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
43 Second Amendment on Phase I Trial NO7VEG 'Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega)': Vega Siri Addendum. Completed NCT00743262 Phase 1, Phase 2
44 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
45 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
46 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
47 A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Completed NCT00098631 Phase 2 lapatinib ditosylate
48 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
49 Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma Completed NCT00387335 Phase 2 sunitinib malate
50 A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors Completed NCT00063895 Phase 1, Phase 2 erlotinib hydrochloride

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Sources

Genetic Tests for Larynx Cancer

About this section
Sources

Anatomical Context for Larynx Cancer

About this section

MalaCards organs/tissues related to Larynx Cancer:

40
Lymph Node, Lung, Thyroid, Breast, Skin, Testes, Endothelial
Sources

Publications for Larynx Cancer

About this section

Articles related to Larynx Cancer:

(show top 50) (show all 3960)
# Title Authors PMID Year
1
Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. 61 46
19546886 2009
2
Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases. 54 61
20052590 2010
3
SH3GL2 gene participates in MEK-ERK signal pathway partly by regulating EGFR in the laryngeal carcinoma cell line Hep2. 54 61
20512084 2010
4
Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues. 54 61
19427146 2009
5
[Expression of E-cadherin and uPA and their prognostic value in carcinoma of human larynx.]. 54 61
20193619 2009
6
Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. 54 61
19724860 2009
7
EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. 54 61
19789511 2009
8
[Expression of EMS1 protein and its clinical significance in laryngeal carcinoma]. 54 61
19947248 2009
9
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. 54 61
19813623 2009
10
The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. 54 61
20108544 2009
11
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? 54 61
19160427 2009
12
Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 54 61
19148533 2009
13
[Impact of tobacco smoking on biologic background of laryngeal squamous cell carcinoma]. 54 61
20301890 2009
14
MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma. 54 61
18236066 2008
15
[Relative factors analysis including carcinoma marker, molecular margin and clinical factors on laryngeal carcinoma recurrence]. 54 61
18800676 2008
16
Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. 54 61
18509272 2008
17
Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect? 54 61
18439947 2008
18
Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. 54 61
17592663 2008
19
EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. 54 61
18172732 2008
20
Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. 54 61
18357366 2008
21
Cortactin expression predicts poor survival in laryngeal carcinoma. 54 61
18268491 2008
22
[Expression of FHIT gene protein in laryngeal carcinoma]. 54 61
18476633 2008
23
[Effect of interferon-gamma on the expression of vascular endothelial growth factor C on Hep-2 laryngeal carcinoma cell lines]. 54 61
18476628 2008
24
[Expression and implication of CD44 and nm23-H1 proteins in laryngeal carcinoma]. 54 61
18476632 2008
25
[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. 54 61
18476631 2008
26
Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells. 54 61
18391576 2008
27
Application of primary cell cultures of laryngeal carcinoma and laser scanning cytometry in the evaluation of tumor reactivity to cisplatinum. 54 61
18519232 2008
28
Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. 54 61
18383901 2008
29
Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. 54 61
18431027 2007
30
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study. 54 61
17888194 2007
31
[Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma]. 54 61
18330257 2007
32
[The expression of MMP-2, E-cadherin in supraglottic carcinoma and their relationship with cervical lymph node metastasis]. 54 61
18062285 2007
33
[Correlation of membrane type I matrix metalloproteinase (MT1-MMP) expression with clinicomorphological features of tumor front in squamous cell carcinoma of the larynx]. 54 61
18080692 2007
34
[Elemene in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice]. 54 61
17634027 2007
35
[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. 54 61
17634026 2007
36
[Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma]. 54 61
17649730 2007
37
[Morphological tumor front grading and matrix metalloproteinases type I expression as a prognostic parameter of the presence of lymph node micrometastases in laryngeal carcinoma]. 54 61
18552024 2007
38
Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. 54 61
17352251 2007
39
The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. 54 61
17264532 2007
40
Maspin nuclear localization is related to reduced density of tumour-associated micro-vessels in laryngeal carcinoma. 54 61
17214364 2006
41
5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. 54 61
17207318 2006
42
[Quantitative analysis of epidermal growth factor receptor mRNA in laryngeal carcinoma by reverse transcription-real time polymerase chain reaction with TagMan probe]. 54 61
17190429 2006
43
Human papillomavirus and Epstein-Barr virus infection, p53 expression, and cellular proliferation in laryngeal carcinoma. 54 61
16891205 2006
44
[Relationship among lymphangiogenesis, vascular endothelial growth factor-C mRNA expression and cervical lymphatic metastasis in laryngeal carcinoma]. 54 61
17039808 2006
45
The expression of Bcl-2 family proteins and spontaneous apoptosis in laryngeal carcinomas. 54 61
17476972 2006
46
[Pronostic value of the immunohistochemical expression of cyclin D1 (DCS6) in epidermoid larynx carcinoma]. 54 61
16881553 2006
47
[Inhibition of eIF families expression and angiogenesis for human laryngeal carcinoma by elemene administration]. 54 61
16408751 2005
48
[Correlation between the prognosis and the expression of survivin in surgical margins of laryngeal squamous cell carcinoma]. 54 61
16176004 2005
49
Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. 54 61
15842640 2005
50
[Effect of expression of p53 in squamous cell carcinoma of larynx and mucosa adjacent to tumor on the biological behavior]. 54 61
16075975 2005
Sources

Variations for Larynx Cancer

About this section

Cosmic variations for Larynx Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM122736330 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.338G>T p.G113V 17:7674229-7674229 0
Sources

Expression for Larynx Cancer

About this section
Search GEO for disease gene expression data for Larynx Cancer.
Sources

Pathways for Larynx Cancer

About this section

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.72 TP53 GSTP1 EGFR CDKN2A CCND1
2
Drug metabolism - cytochrome P450 36
Show member pathways
 12.69 NME1 NAT2 GSTP1 GSTM3 GSTM1
3
Pathways in cancer 36
12.58 TP53 TERT GSTP1 GSTM3 GSTM1 EGFR
4
DNA Damage Response 1
Show member pathways
 12.22 TP53 MIR106B CDKN2A CCND1
5
Gastric cancer 36
Show member pathways
 12.22 TP53 TERT GSTP1 GSTM3 GSTM1 EGFR
6
Human T-cell leukemia virus 1 infection 36
12.18 TP53 TERT CDKN2A CCND1
7
Proteoglycans in cancer 36
12.12 TP53 MIR21 EGFR CCND1
8
Fluid shear stress and atherosclerosis 36
11.92 TP53 GSTP1 GSTM3 GSTM1
9
Glioblastoma Multiforme 63
11.8 TP53 EGFR CDKN2A CCND1
10
MicroRNAs in cancer 36
11.77 TP53 MIR423 MIR34C MIR34A MIR21 MIR106B
11
Validated targets of C-MYC transcriptional activation 1
11.64 TP53 TERT NME1
12
Bladder cancer 36 1
11.57 TP53 EGFR CDKN2A CCND1
13
Regulation of Telomerase 1
11.52 TERT EGFR CCND1
14
Platinum drug resistance 36
11.42 TP53 GSTP1 GSTM3 GSTM1 CDKN2A
15
Photodynamic therapy-induced AP-1 survival signaling. 1
11.38 TP53 EGFR CDKN2A CCND1
16
miRNAs involved in DNA damage response 1
11.32 TP53 MIR34C MIR106B CCND1
17
Busulfan Pathway, Pharmacodynamics 60
Show member pathways
 11.31 NAT2 GSTP1 GSTM1
18
Metastatic brain tumor 1
11.06 TP53 MIR34C MIR148A
Sources

GO Terms for Larynx Cancer

About this section

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MIR423 MIR21 MIR148A MIR106B HSPB1 GSTP1

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.88 TP53 TERT NME1 MIR21
2 negative regulation of apoptotic process GO:0043066 9.85 TP53 TERT MIR21 HSPB1 GSTP1 EGFR
3 miRNA mediated inhibition of translation GO:0035278 9.77 MIR21 MIR148A MIR106B
4 negative regulation of protein kinase activity GO:0006469 9.74 HSPB1 GSTP1 CDKN2A
5 cellular response to drug GO:0035690 9.72 TP53 NME1 EGFR
6 cellular response to hypoxia GO:0071456 9.71 TP53 TERT MIR34A MIR106B
7 positive regulation of epithelial cell proliferation GO:0050679 9.7 NME1 EGFR CCND1
8 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.65 TERT EGFR CCND1
9 glutathione metabolic process GO:0006749 9.63 GSTP1 GSTM3 GSTM1
10 positive regulation of connective tissue replacement GO:1905205 9.58 MIR34C MIR34A
11 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.56 TP53 EGFR
12 mitotic G1 DNA damage checkpoint GO:0031571 9.54 TP53 CCND1
13 xenobiotic catabolic process GO:0042178 9.51 GSTM3 GSTM1
14 negative regulation of smooth muscle cell chemotaxis GO:0071672 9.49 MIR34A GSTP1
15 nitrobenzene metabolic process GO:0018916 9.43 GSTM3 GSTM1
16 glutathione derivative biosynthetic process GO:1901687 9.33 GSTP1 GSTM3 GSTM1
17 cellular detoxification of nitrogen compound GO:0070458 9.32 GSTM3 GSTM1
18 response to UV-A GO:0070141 9.26 EGFR CCND1
19 replicative senescence GO:0090399 9.13 TP53 TERT CDKN2A
20 gene silencing by miRNA GO:0035195 9.1 MIR423 MIR34C MIR34A MIR21 MIR148A MIR106B

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.72 MIR423 MIR34A MIR21 MIR148A MIR106B
2 protein kinase binding GO:0019901 9.63 TP53 HSPB1 GSTP1 EGFR CDKN2A CCND1
3 glutathione transferase activity GO:0004364 9.43 GSTP1 GSTM3 GSTM1
4 enzyme binding GO:0019899 9.43 TP53 NME1 GSTM3 GSTM1 EGFR CCND1
5 glutathione binding GO:0043295 8.8 GSTP1 GSTM3 GSTM1
Sources

Sources for Larynx Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....